PubMed Health⌕ Search

Biomedical subjects

F Reymann

Publications and source records attributed to F Reymann.

At least 37 records · Page 2Linked to original sources
PubMed1981

Treatment of multiple squamous cell carcinomas of the skin in an immunosuppressed patient.

A patient receiving immunosuppressive treatment through 7 years after kidney transplantation has developed 84 skin tumors during the last 3 1/2 years. 28 squamous cell carcinomas, which all were histologically highly differentiated, could not clinically be distinguished from 49 keratoses. The problem of therapy is rather delicate. In this case the patient has been followed by regular checkups four times a year and all new tumors have been removed by curettage.

Carcinoma, Squamous Cell↗
PubMed1981

Treatment of dyskeratosis follicularis Darier with the retinoic acid derivative Ro 10-9359 (Tigason).

The results of treatment of 29 patients with Darier's disease with the aromatic retinoid Ro 10-9359 are reported. Therapeutic tests for a period of more than 18 months seem to justify its use in Darier's disease. With a modest dose it is possible to keep the symptoms at an acceptable level, i. e., 50% clearing or more without too troublesome side effects. Because of the side effects the dosage must be fixed individually. It is pointed out that with the development of Ro 10-9359, an efficient remedy for Darier's disease has become available for the first time.

Adult↗
PubMed1980

Basal cell carcinoma of the skin recurrence rate after different types of treatment. A review.

On the basis of own investigations and a survey of the literature, it is shown that the recurrence rate following various types of treatment used for basal cell carcinoma (BCC) is somewhat higher than generally assumed. Irrespective of the method used, the results obtained after treatment of recurrent BCCs are less favorable. Consequently, it is strongly recommended that patients be closely controlled for a period of years following treatment and that only specially trained doctors carry out the treatment. The possibility of centralizing treatment of BCC of the skin to dermatological units is put forward.

Antineoplastic Agents↗
PubMed1979

Squamous cell carcinoma of the skin and internal malignant neoplasms.

This study comprised 211 patients in whom squamous cell carcinomas of the skin (SCC) had been diagnosed in the Department of Dermatology from 1950 to 1959. These patients were followed up as of Jan 1, 1976, to establish the incidence of internal malignant neoplasms. A systematic statistical study was carried out through the population register, the central register for death certificates, and the Danish Cancer Register. These registers cover the entire country, making it possible to calculate the number of expected cases of internal cancer during the above-mentioned prolonged period of observation. The investigation did not show increased incidence of internal malignant neoplasms in connection with SCC of the skin.

Adult↗
PubMed1979

Metastases in dermatological patients with squamous cell carcinoma.

Two hundred eleven patients in whom squamous cell carcinoma (SCC) of the skin had been diagnosed between 1950 and 1959 were followed up from Jan 1, 1976, to establish the incidence of metastases. A systemic study was carried out through follow-up examinations and tracing through population registers. We found 3.3% metastases in 153 patients with skin SCC and 11% metastases in 55 patients with labial SCC. Three patients with genital SCC were free of metastases. These results and the available literature on patients with SCC of osteomyelitic foci and scars from burns or x-ray treatment indicate that sharp distinctions must be made among three groups of SCC; mucocutaneous, primary cutaneous, and cutaneous SCC secondary to inflammatory and degenerative processes. The incidence of metastases in the three groups is approximately 11%, 3%, and 10% to 30%, respectively. Percentages found are important to dermatology clinics because skin SCC should be considered a malignant tumor with a higher incidence of metastases than previously assumed.

Aged↗
PubMed1979

Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study.

During the period 1966-1968, 88 patients with a total of 95 basal cell carcinomas were treated with 5% 5-fluorouracil ointment. A follow-up study carried out from November 1977 to January 1978 revealed a total of 12 recurrences in 56 surviving patients with 56 basal cell carcinomas. The recurrence rate is thus 21.4%. It is concluded that there is hardly any indication for using 5-fluorouracil in local treatment of nodular basal cell carcinoma.

Administration, Topical↗
PubMed1979

The retinoic acid derivative Ro 11-1430 (Tasmaderm) in patients with acne vulgaris not tolerating retinoic acid. A controlled multicenter trial against placebo.

In a double-blind randomized comparative multicenter trial, consisting of 29 patients with acne vulgaris who were unable to tolerate daily applications of retinoic acid, the retinoic acid derivative Ro 11--1430 (0.1% vanishing cream) was compared in a 6--8 weeks topical treatment with vanishing cream alone (placebo). Regarding efficacy, for most criteria measured the response was always better with Ro 11--1430 than with placebo, although the differences were not always statistically significant for several reasons, one probably being the small number of patients in the trial. Regarding tolerance, both treatments were satisfactory. Ro 11---1430 and placebo did not differ significantly regarding frequency and severity of erythema, desquamation and burning. These results suggest that treatment with Ro 11--1430 should be considered in acne patients who are unable to use retinoic acid due to severe local reactions.

Acne Vulgaris↗
PubMed1978

Treatment of basal cell carcinoma of the skin with ultrasoft X-rays.

The results of a follow-up study carried out in 1975-76 are described. The study involved 454 patients who had received ultrasoft X-ray treatment for basal cell carcinomas during the period 1965-1969. In females, the percentage of recurrence was 4.9, in males, 11.9. The figures indicating the frequency of recurrence are minimum ones; the patients were selected to a certain extent, the large tumors being treated surgically. The most important result of the study was the observation that approximately 30% of the X-ray scars examined were so disfiguring from a cosmetic point of view that they must be characterized as unacceptable. The indications for X-ray treatment of basal cell carcinomas should, consequently, be limited to deep-growing tumors or tumors which are not well demarcated, and to tumors in elderly patients, who should be spared surgery.

Adult↗
PubMed1978

Relationship between arsenic intake and internal malignant neoplasms.

An attempt has been made to assess the carcinogenic effect of arsenic intake by analyzing a group of patients who were treated with arsenic for various skin diseases in the 1930s. When compared with the expected incidence of malignant internal neoplasms, based on figures obtained from the Danish Cancer Registry, a significant increase in the incidence of internal malignant neoplasms was observed in females with multiple basal cell carcinomas. A group comprising 53 patients with arsenic keratoses presented a considerable increase in the incidence of internal malignant neoplasms. However, these patients were so specifically selected that no regular statistical analysis can be made of this group. It may be said that arsenic has a carcinogenic effect even in the relatively small doses applied in dermatological therapy.

Aged↗
PubMed1977

Treatment of Keratoacanthomas with currettage.

The present paper reports the results of a follow-up study of 47 patients with keratoacanthomas treated solely with currettage. Only one recurrence was seen, and the cosmetic results were much better than those obtained with other types of treatment. Curettage must be considered the treatment of choice for keratoacanthomas on the face.

Aged↗
PubMed1977

The retinoic acid derivative Ro 11-1430 in Acne vulgaris. A controlled multicenter trial against retinoic acid.

In a double-blind controlled multicenter trial consisting of 257 patients with acne vulgaris an 8-week topical treatment with the retinoic acid derivative Ro 11-1430 (0.1% lotion) was compared with vitamin A acid (0.05% lotion) and the lotion alone (placebo). In reducing the number of comedones vitamin A acid was superior to Ro 11-1430, which was significantly better than placebo. The reduction in number of papules and pustules was not statistically significant on either treatment. Local side effects, i.e. erythema, desquamation, burning and pruritus occurred more frequently and were more severe on vitamin A acid than on Ro 11-1430 and placebo which did not differ. No correlation was found between incidence and severity of local reactions and therapeutic effect.

Acne Vulgaris↗
PubMed1977

Treatment of psoriasis vulgaris with a new retinoic acid derivative Ro 10-9359; An uncontrolled clinical trial.

The retinoic acid derivative Ro 10-9359, given orally in maximum daily doses of 100 mg to 15 patients with psoriasis vulgaris, led to clearing of the lesions in 8 patients. The average period of treatment was 9 weeks. In 14 patients side-effects were observed, the most important being palmo-plantar desquamation, shivering, thirst and diffuse hair loss. In 2 patients scaling led to withdrawal. In 6 patients abnormal alkaline phosphatase and glutamic-aspartatic transaminase values, partly transient, developed (glutamicaspartatic transaminase, p less than 0.01).

Alkaline Phosphatase↗
PubMed1977

Efficacy of bufexamac (NFN) cream in skin diseases. A double-blind multicentre trial.

The effect of a new non-steroid anti-inflammatory substance (bufexamac) in a special constituent was compared with that of 0.1% triamcinolone acetonide, 1% hydrocortisone cream, and placebo during a double-blind multicentre trial. The clinical effect of these four creams was studied in 193 patients receiving treatment for the following skin disorders: atopic dermatitis, allergic contact dermatitis, and non-allergic contact dermatitis, as well as dermatitis seborrheica. After 2 and 4 weeks' treatment, when 193 and 157 patients, respectively, were re-examined, the effect of triamcinolone acetonide and hydrocortisone cream was significantly better, than that obtained with bufexamac in the cream basis employed. On the other hand, no statistically significant difference in effect between bufexamac and placebo cream was observed.

Administration, Topical↗
PubMed1976

Treatment of acne vulgaris with the retinoic acid derivative Ro 11-1430. A controlled clinical trial against retinoic acid.

In a double-blind, randomized, group-comparative clinical trial, 31 patients with acne vulgaris received topical treatment for 6-8 weeks with a lotion containing either 0.05% retinoic acid or 0.1% of the retinoic acid derivative Ro 11-1430. The side-effects erythema, desquamation and burning were significantly less frequent with Ro 11-1430 than with retinoic acid. The treatments appeared to be approximately equally effective in reducing the number of acne elements, but due to the limited number of patients studied, the trial was admittedly not sufficient to detect differences with regard to therapeutic efficacy.

Acne Vulgaris↗